-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data...
Hence then, the article about ascletis presents full analysis of phase ib study of asc30 oral tablet phase ib study of asc30 injection and preclinical study of combination of asc31 and asc47 at obesityweek 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025 )
Also on site :
- Tornado warning issued, and quickly cancelled, over Alhambra
- Governor Hochul: Annual statewide donation drive is complete
- Skier dies in collision with tree at Colorado’s Aspen Mountain, resort officials confirm